Hematology · Medical Literature
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 440-453, July 30, 2026.
Clinical relevance
In patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy (including a prior anti-CD38 monoclonal antibody and lenalidomide), does teclistamab monotherapy improve progression-free survival compared with investigator's choice of pomalidomide/bortezomib/dexamethasone (PVd) or carfilzomib/dexamethasone (Kd)? __SNAPSHOT__ {"studyDesign":"Phase 3, randomized, open-label, multicenter, active-controlled trial (MajesTEC-9; NCT05572515); reported here as a pre-specified interim analysis","setting":"International; 24 countries; community and academic oncology centers","sampleSize":"n=593 (teclistamab: n=296; PVd or Kd: n=297); 574 received study treatment (teclistamab: n=291; PVd/Kd: n=283)","population":"Adults with relapsed or refractory multiple myeloma (RRMM), 1–3 prior lines of therapy including a prior anti-CD38 monoclonal antibody and lenalidomide, ECOG PS 0–2, documented progressive disease or failure of immediate prior line; prior BCMA-targeted therapy was excluded. Median age 70 years (range 34–86); ~30% aged ≥75 years; ~85% anti-CD38 refractory; ~79% lenalidomide refractory; >90% refractory to immediate prior line; ~35% high-risk cytogenetics; ~20% extramedullary disease; ~15% ISS stage III","intervention":"Subcutaneous teclistamab with step-up dosing (0.06 mg/kg then 0.3 mg/kg), then 1.5 mg/kg weekly (cycles 1–2), 3 mg/kg every 2 weeks (cycles 3–6), and 3 mg/kg every 4 weeks (cycle 7 onward). Antimicrobial prophylaxis and immunoglobulin replacement were recommended.","comparator":"Investigator's choice of PVd (pomalidomide + bortezomib + dexamethasone) or Kd (carfilzomib + dexamethasone); 69.6% received Kd and 30.4% received PVd","primaryOutcome":"Progression-free survival (PFS) as assessed by an independent review committee (IRC)","followUp":"Median follow-up: 17.3 months (interim analysis)","fundingSource":"Industry (Johnson & Johnson)"}
Key findings
PRIMARY OUTCOME — PFS: At the interim analysis (median follow-up 17.3 months), median PFS was not reached with teclistamab versus 8.2 months with PVd/Kd (HR 0.29; 95% CI 0.23–0.38; p<0.001), representing a 71% reduction in the risk of disease progression or death. The estimated 18-month PFS rate was 69.8% vs. 26.9% (absolute difference: 42.9 percentage points [calculated]). OVERALL SURVIVAL: Teclistamab significantly reduced the risk of death (HR 0.60; 95% CI 0.43–0.83; p=0.002), corresponding to an 18-month OS rate of 79.2% vs. 68.6% (absolute difference: 10.6 percentage points [calculated]). RESPONSE DEPTH: ORR was 84.5% vs. 54.2% (OR 4.62; 95% CI 3.13–6.83; p<0.001). Complete response or better (≥CR) was achieved in 65.9% vs. 16.8% (OR 10.42; 95% CI 6.89–15.76; p<0.001). ≥VGPR: 80.1% vs. 36.4%. Median duration of response was not reached vs. 13.4 months (95% CI 10.4–17.3); estimated 18-month DOR rate 80.6% vs. 40.1%. MRD NEGATIVITY (≥CR at 10⁻⁵): 38.5% vs. 6.7% in the intent-to-treat population (OR 8.56; 95% CI 5.14–14.26); among MRD-evaluable patients, 86.4% vs. 45.5% (OR 6.80; 95% CI 3.05–15.16). PATIENT-REPORTED OUTCOMES: Median time to worsening of MM symptoms was not reached with teclistamab vs. 19.48 months with PVd/Kd (HR 0.50; 95% CI 0.36–0.71; p<0.001); 18-month event-free rates: 73.5% vs. 55.1%. SUBGROUP CONSISTENCY: PFS benefit was consistent across clinically relevant subgroups, including patients refractory to lenalidomide or daratumumab and those with high-risk cytogenetics. SAFETY: Any-grade TEAEs occurred in 99.7% (teclistamab) vs. 97.9% (PVd/Kd); grade 3/4 TEAEs in 84.9% vs. 76.3%. CRS occurred in 66.0% of teclistamab-treated patients; grade 3 CRS in 0.7%; no grade 4 or 5 CRS; all resolved without treatment discontinuation. ICANS: grade 1/2 in 3.8%, grade 3 in 0.3%. Grade 3/4 neutropenia: 54.3% (teclistamab) vs. 22.3% (PVd/Kd). Grade 3/4 infections: 41.6% vs. 29.0%. Grade 5 infections (fatal): 5.5% (teclistamab) vs. 2.8% (PVd/Kd), with most fatal infections occurring in patients with low IgG levels. Hypogammaglobulinemia was common in both arms. Grade 3/4 thrombocytopenia was lower with teclistamab (10.7% vs. 21.2%). Discontinuations due to TEAEs: 10.7% (teclistamab) vs. 13.1% (PVd/Kd). Median treatment duration: 13.1 months vs. 7.0 months. NNT for one additional MRD-negative CR or better at 18 months (ITT, 38.5% vs. 6.7%): approximately 3 (calculated). NNH for one additional grade 5 infection: approximately 37 (calculated).
Practice implications
IMPORTANT LIMITATION: Only the abstract is available for direct review; specific subgroup data granularity, full Kaplan-Meier curves, OS maturity details, and complete safety tables were sourced from conference presentations and contemporaneous peer-reviewed commentaries rather than from the primary publication text. Conclusions should be interpreted accordingly. WHAT THE STUDY ESTABLISHED: MajesTEC-9 is a positive phase 3 randomized trial demonstrating that teclistamab monotherapy produces statistically significant and clinically meaningful improvements in PFS, OS, ORR, depth of response (≥CR, MRD negativity), duration of response, and patient-reported symptom outcomes in anti-CD38/lenalidomide-exposed RRMM patients with 1–3 prior lines of therapy compared with standard investigator-choice doublet or triplet regimens. The OS benefit at an interim analysis with only 17.3 months of median follow-up is notable, though OS data will require further maturation given that median OS was not reached in either arm. The PFS HR of 0.29 is among the most impressive effect sizes reported in phase 3 RRMM trials and the magnitude (42.9 percentage-point absolute 18-month PFS difference) is clinically striking. WHAT WAS NOT ESTABLISHED: The study does not define optimal sequencing relative to teclistamab/daratumumab combinations (MajesTEC-3), CAR-T therapies, or novel triplets in the RRMM space. Long-term OS data are immature. The trial does not inform whether response depth (MRD negativity) translates to cure or sustained remission off therapy. Outcomes beyond 18 months and after subsequent lines of therapy are not yet reported. APPLICABILITY: The population studied (predominantly anti-CD38 refractory, lenalidomide refractory, older adults with median age 70 years, ~35% high-risk cytogenetics, ~20% extramedullary disease) is broadly representative of a challenging real-world RRMM population, including those commonly seen in community oncology settings. Patients with prior BCMA-targeted therapy were excluded; findings do not apply to this group. Patients with ECOG PS >2 were not enrolled. CLINICAL IMPORTANCE: The magnitude of benefit across PFS, OS, response depth, and PROs, combined with subgroup consistency, suggests robust clinical importance beyond statistical significance. However, the infection risk — particularly a 5.5% fatal infection rate — is clinically significant and necessitates rigorous prophylaxis protocols, close monitoring (especially in the first 6 months), and IgG replacement. CRS, while common, was predominantly low-grade. The step-up dosing schedule and CRS monitoring requirements present logistical challenges for non-specialized community settings. PRACTICE IMPLICATIONS: These data, along with MajesTEC-3, collectively reposition teclistamab-based therapy as a viable standard-of-care option in 2nd-line and beyond RRMM after anti-CD38 and lenalidomide exposure. Regulatory label expansion (current FDA approval requires ≥4 prior lines) will depend on submission and agency review of the full MajesTEC-9 dataset. __LIMITATIONS__ 1. OPEN-LABEL DESIGN: The absence of blinding introduces potential performance and assessment bias for subjective endpoints; PFS was adjudicated by an IRC, which partially mitigates this concern for the primary endpoint. 2. INTERIM ANALYSIS: OS data are immature (median follow-up 17.3 months); OS HR of 0.60 may change with longer follow-up, and the OS benefit should be interpreted cautiously until data are more mature. 3. ACTIVE COMPARATOR HETEROGENEITY: The control arm permitted investigator choice of either PVd or Kd — two regimens with different mechanisms and toxicity profiles (69.6% received Kd) — introducing heterogeneity that limits within-arm interpretation. 4. INDUSTRY SPONSORSHIP: Funded by Johnson & Johnson (manufacturer of teclistamab), introducing potential for design, analysis, and reporting bias. 5. GENERALIZABILITY: Prior BCMA-targeted therapy was excluded, limiting applicability to a growing patient population. Patients with ECOG PS >2 were also excluded. Step-up dosing and CRS monitoring may not be feasible in all community settings. 6. SURROGATE ENDPOINTS: MRD negativity is not yet validated as a surrogate for OS in RRMM; its clinical implication as a treatment target remains investigational. 7. COMPARATIVE CONTEXT: MajesTEC-9 does not compare teclistamab monotherapy to the teclistamab/daratumumab combination (MajesTEC-3) or to emerging quadruplet regimens, making optimal sequencing decisions challenging. 8. ABSTRACT-ONLY LIMITATION: Full methodological details (randomization concealment, stratification adequacy, handling of missing data, crossover rates, and complete adverse event tables) are not assessable from the abstract alone. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ In anti-CD38/lenalidomide-exposed RRMM with 1–3 prior lines of therapy, teclistamab monotherapy produced a 71% reduction in the risk of disease progression or death (HR 0.29; p<0.001) and a significant OS benefit (HR 0.60; p=0.002) versus PVd or Kd in this phase 3 trial, with an absolute 18-month PFS difference of approximately 43 percentage points. Fatal infections occurred in 5.5% of teclistamab-treated patients, underscoring the imperative for aggressive antimicrobial prophylaxis and immunoglobulin replacement from treatment initiation. These data, pending OS maturity and regulatory review, strongly support repositioning teclistamab-based therapy as a standard-of-care option in early RRMM lines after anti-CD38 and lenalidomide exposure, provided appropriate infectious disease safeguards and monitoring infrastructure are in place.